Pharmaceuticals News and Research

RSS

Drug shortages are having major negative effects on patient care and hospital costs

A study to be published in the October 1, 2004, issue of the American Journal of Health-System Pharmacy finds that ongoing drug shortages are having far-ranging, negative effects on patient care and hospital costs.

26 Sep 2004

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.

26 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Genes in poppy could hold the key to producing improved pain management pharmaceuticals

"The genes we found behaved differently in Norman compared to standard morphine producing poppies and were consistently associated with the blockage in morphine synthesis and with the accumulation of thebaine and oripavine," Dr Larkin says.

23 Sep 2004

PA Consulting sells drug delivery venture, Meridica, to Pfizer

Pfizer and PA Consulting Group have announced the signing of a transaction in which Pfizer will purchase the remaining 90% ownership of Meridica Limited

23 Sep 2004

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

GlaxoSmithKline currently sells zidovudine (sold as Retrovir®), lamivudine (sold as Epivir®) and the combination of the two molecules (sold as Combivir®) across the region.

22 Sep 2004

University of Arizona spin-off investigates DNA damage to human skin

Niadyne, Inc., a Tucson-based spin-off biopharmaceutical company co-founded by two University of Arizona professors, has received a Small Business Innovation Research grant of nearly $750,000 to continue investigating the prevention of DNA damage to human skin

22 Sep 2004

Investigation into the potential for designing drug treatments based on a person’s genetic makeup

Most current drugs are not effective for 100 per cent of the population and some work in as few as 30 to 50 per cent of cases. Pharmacogenetics, the study of how genetic factors influence a person’s response to a drug, is seen as a way of making treatments as safe and effective as possible for every individual.

20 Sep 2004

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

BBC focuses on the rise of complementary or alternative medicines

Broadcaster Anna Ford investigates why people are turning to CAM in a new six part BBC Radio Four series, The Other Medicine. Is there any evidence that CAM works, is it harmful and should the CAM industry, worth £1.6 billion a year, be made more available on the NHS?

20 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Link between eosinophils and asthma

Mayo Clinic researchers have used a comparative genomic strategy to demonstrate a causative link between eosinophils, a rare type of white blood cell, and asthma.

18 Sep 2004

Wyeth supports FDA recommendation to strengthen antidepressant labeling

Statement by Wyeth Pharmaceuticals supporting the U.S. Food and Drug Administration (FDA) Joint Advisory Committee’s recommendation to strengthen the product labels across the antidepressant category regarding use in the pediatric population.

16 Sep 2004

One-third to buy cheaper Canadian drugs, 100 million find insurance coverage cut or costlier

Faced with a double-barreled crisis of shrinking health care coverage and fast-rising medical costs, two out of three American adults (67 percent) now think health care coverage should be a “guarantee” as in Canada, Britain and other nations.

16 Sep 2004

ChemGenex discovers five new depression genes

ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.

16 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Labor says it would fund the public education anti-smoking campaign, if elected

Australian Medical Association (AMA) President, Dr Bill Glasson, said today that Labor’s promise to inject another $21 million into anti-smoking awareness campaigns would send a strong message to the community to quit the killer habit.

16 Sep 2004

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Vasogen has announced that comprehensive results from the Company's phase II trial of Celacade (immune modulation therapy) in advanced chronic heart failure patients were published in the September 15 issue of the Journal of the American College of Cardiology (JACC).

16 Sep 2004

Pharmaceuticals News and Research

Drug shortages are having major negative effects on patient care and hospital costs

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

Elan and Wyeth receive patents for Alzheimer's disease treatments

Genes in poppy could hold the key to producing improved pain management pharmaceuticals

PA Consulting sells drug delivery venture, Meridica, to Pfizer

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

University of Arizona spin-off investigates DNA damage to human skin

Investigation into the potential for designing drug treatments based on a person’s genetic makeup

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

BBC focuses on the rise of complementary or alternative medicines

European positive for Cymbalta and Xeristar

Link between eosinophils and asthma

Wyeth supports FDA recommendation to strengthen antidepressant labeling

One-third to buy cheaper Canadian drugs, 100 million find insurance coverage cut or costlier

ChemGenex discovers five new depression genes

RNAi enlisted in hunt for prawn vaccines

Labor says it would fund the public education anti-smoking campaign, if elected

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News